New additions strengthen Quidel's management team
This article was originally published in Clinica
Executive Summary
Point-of-care diagnostics firm Quidel has appointed several executives to its management team: Tim Stenzel as chief scientific officer; Larry Mimms as vice-president of R&D; and Ratan Borkar as vice-president of business development. They join Judi Tilghman, who was appointed vice-president of technology assessment in July. Dr Stenzel, who was previously vice-president and chief medical officer of molecular diagnostics company Asuragen, will be responsible for technology assessment and implementing Quidel's molecular diagnostics strategy. Dr Mimms most recently headed his own company, VDx Laboratories, and has also held a number of senior positions with Gen-Probe. Mr Borkar was previously an investment banker for JP Morgan, while Dr Tilghman has worked for EMD Chemicals, Luminex and Sigma Aldrich in strategic planning and business development roles.